When was Abscint founded?

Abscint was founded in 2020 and raised its 1st funding round 2 years after it was founded.

Where is Abscint located?

Abscint is headquartered in Ganshoren, Belgium.

How many employees does Abscint have?

As of Aug 31, 2026, the latest employee count at Abscint is 8.

Is Abscint a funded company?

Abscint is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Dec 05, 2022.

When was the latest funding round of Abscint?

Abscint's latest funding was a $***** Seed round on Dec 05, 2022, with participation from 2 investors.

Where does Abscint rank among its competitors?

Abscint ranks 27th amongst 92 active competitors, of which 24 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was SmartHealth, which secured $300K in Nov, 2024.

Who are the top competitors of Abscint?

Abscint's top competitors include GEN inCode, Proxim Diagnostics and Notable Labs. Among them, SmartHealth secured the most recent funding round in November, 2024.

Abscint - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of radiolabelled single domain antibodies to diagnose cancer and cardiac diseases. The company offers ABSCINT-HER2 for the detection of HER2 positive cells in the brains and ABSCINT-206 for the detection of immune cells in granuloma CD-206 positive macrophages in the heart.

Website: abscint.com
Email ID: *****@abscint.com

Key Metrics

Founded Year

2020

Location

Ganshoren, Belgium

Stage

Acquired

Total Funding

$1.05M in 1 round

Latest Funding Round

Seed, Dec 05, 2022, $*****

Investors

Qbic Fund & 1 more

Ranked

27^th among 92 active competitors

Employee Count

8 as on Aug 31, 2026

Similar Companies

GEN inCode & 119 more

Exit Details

Acquired by Curium (Aug 10, 2026)

View Abscint's full profile

Abscint is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Abscint CIN: 0749.828.410 , Belgium, Active	Jul 05, 2020	-	2 (As on Dec 31, 2022)	-

Abscint got acquired by Curium on Aug 10, 2026.

Click here to take a look at Abscint's acquisition in detail

Abscint has raised a total funding of $1.05M over 1 round. Its latest funding round was a Seed round on Dec 05, 2022 for $*****. 2 investors participated in its latest round. Abscint has 2 institutional investors.

Here is the list of recent funding rounds of Abscint:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 05, 2022	6589792	Seed	1663875	4724068	6207914	4559858

Access funding benchmarks and valuations. Sign up today!

View details of Abscint's funding rounds and investors

Abscint's employee count trend

Abscint has 8 employees as of Aug 26. Here is Abscint's employee count trend over the years:

Uncover Abscint's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Abscint include GEN inCode, Proxim Diagnostics and Notable Labs. Here is the list of Top 10 competitors of Abscint, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	GEN inCode 2018, Manchester (United Kingdom), Public	Developer of precison medicines by combining genetic and clinical data for cardiac disease monitoring	$5.46M	Downing, Maven Capital Partners & 4 others	57/100
2nd	Proxim Diagnostics 2010, Sunnyvale (United States), Series B	Developer of a handheld immunodiagnostic device for cardiac vascular diseases	$22.9M	BioMerieux, UCLA Ventures & 1 others	52/100
3rd	Notable Labs 2014, San Francisco (United States), Series B	Precision medicine and clinical decision support solutions for brain cancer	$72.2M	Y Combinator, B Capital & 31 others	50/100
4th	SmartHealth 1979, Irvine (United States), Series B	Developer precision diagnostics for vascular, metabolic, and oncological diseases	$17.3M	-	49/100
5th	Realview Imaging 2008, Yokneam Illit (Israel), Series C	Provides 3D holographic display based solutions for medical imaging applications	$25M	OurCrowd, ADIP & 10 others	49/100
6th	Zora Biosciences 2016, Espoo (Finland), Funding Raised	Provider of diagnostic solutions for cardiovascular diseases and cancer	-	Voima Ventures, Europa	46/100
7th	Diadexus 1997, San Francisco (United States), Acquired	Innovating clinical diagnostics with advanced enzyme and immunoassay technologies	$49.2M	Brookside Capital, Scale Venture Partners ... & 4 others	45/100
8th	Exsegen 2020, Hyderabad (India), Funding Raised	Developer of minimally invasive brain cancer diagnostics and treatments	-	C-CAMP	43/100
9th	Magnisense 2003, Paris (France), Series A	Develops emergency diagnostic tests for cardiovascular diseases	$11.5M	Noshaq, Concorde & 1 others	39/100
10th	Boston Heart Diagnostics 2007, Framingham (United States), Acquired	Developer of diagnosis for personalized care for cardiovascular diseases	$10.3M	Bain Capital Ventures, Silversmith Capital Partners ... & 9 others	39/100
27th	Abscint 2020, Ganshoren (Belgium), Acquired	Developer of radiolabelled single domain antibodies to diagnose cancer and cardiac diseases	$1.05M	Qbic Fund, Uzbrussel	40/100